The demand for GLP-1s isnt just about filling prescriptions
Tirzepatide is also the only incretin medication FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity
Because of their substantial benefit on some of the most highly prevalent disorders worldwide, GLP-1RAs have been hailed as game changers 8,9 and breakthrough drugs 10 , with an estimated market value of US$22.4 billion in 2022 and a compound annual growth rate of around 9.6% between 2023 and 2032 11
GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their attributes such as body weight loss, protection of islet cells, promotion of islet cell proliferation and minimal side effects
Peptides for Cardiovascular Research: Vasodilatory, Cardioprotective & Metabolic Compounds Ranked 7 compounds studied across vasodilatory, cardioprotective, and GLP-1 cardiac outcome research with 3 published CVOTs and Phase 3 mitochondrial trial data ranked by evidence depth
The validity of major CI diagnoses in the Danish National Patient Register has been previously assessed and it was found to have positive predictive values more than 80% [17, 18]
